Advances in clinical pharmacotherapy for neonatal Ureaplasma urealyticum infection.
10.7499/j.issn.1008-8830.2503019
- Author:
Bei-Bo CAI
1
;
Fei-Fei CHEN
1
;
Fang LUO
1
Author Information
1. Department of Clinical Pharmacy, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
- Publication Type:English Abstract
- Keywords:
Macrolides;
Neonate;
Therapy;
Ureaplasma urealyticum
- MeSH:
Humans;
Ureaplasma Infections/drug therapy*;
Infant, Newborn;
Ureaplasma urealyticum;
Anti-Bacterial Agents/therapeutic use*
- From:
Chinese Journal of Contemporary Pediatrics
2025;27(10):1286-1290
- CountryChina
- Language:Chinese
-
Abstract:
Ureaplasma urealyticum (UU) is a common pathogen colonizing or infecting the neonatal respiratory tract. It can be vertically transmitted from mother to infant, irrespective of the duration of premature rupture of membranes and the mode of delivery. UU infection is an important factor contributing to preterm birth and low birth weight and is closely associated with adverse outcomes such as bronchopulmonary dysplasia and neurodevelopmental impairment. Given the immaturity of neonatal immune and organ systems, pharmacologic treatment must balance efficacy and safety. Currently, no unified standard regimen has been established for the treatment of neonatal UU infection. This review summarizes pharmacotherapeutic options for neonatal UU infection to inform clinical practice.
